Online citations, reference lists, and bibliographies.
← Back to Search

The Role Of Nanotechnology In The Treatment Of Viral Infections

Lavanya Singh, H. Kruger, G. Maguire, T. Govender, R. Parboosing
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery. These are predominantly due to the particle size (which affects bioavailability and circulation time), large surface area to volume ratio (enhanced solubility compared to larger particles), tunable surface charge of the particle with the possibility of encapsulation, and large drug payloads that can be accommodated. These properties, which are unlike bulk materials of the same compositions, make nanoparticulate drug delivery systems ideal candidates to explore in order to achieve and/or improve therapeutic effects. This review presents a broad overview of the application of nanosized materials for the treatment of common viral infections.
This paper references
10.2147/IJN.S76517
Sustained-release nanoART formulation for the treatment of neuroAIDS
R. Jayant (2015)
10.2217/17435889.4.1.105
Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
M. Muthu (2009)
10.1056/NEJMoa1211917
Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
M. Blanken (2013)
10.1016/J.AJPS.2014.06.002
Nanotechnology and vaccine development
Migyeong Kim (2014)
10.1016/j.vaccine.2009.05.029
Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.
C. Herzog (2009)
10.1021/es9035557
Ion release kinetics and particle persistence in aqueous nano-silver colloids.
J. Liu (2010)
10.2174/1381612053764869
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
G. Barbaro (2005)
10.1016/J.ADDR.2005.09.011
Characterization of dendrimers.
A. Caminade (2005)
10.1038/nrd1033
Effect of pegylation on pharmaceuticals
J. Harris (2003)
10.1201/B11076-11
Nanotechnology in Controlling Infectious Disease
R. M. Amin (2011)
10.1007/s00253-013-5422-8
Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: A review
Avinash P. Ingle (2013)
10.1080/10934520802177813
Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and low-pressure UV light
D. Gerrity (2008)
10.1097/QAI.0b013e3182a99590
Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial
B. Rodriguez (2013)
10.1126/SCIENCE.1114397
Toxic Potential of Materials at the Nanolevel
A. Nel (2006)
10.1016/J.EJPB.2006.11.009
A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes.
K. Letchford (2007)
10.1016/j.ejpb.2011.01.007
State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery.
R. Mueller (2011)
10.1038/sj.clpt.6100400
Nanoparticles in Medicine: Therapeutic Applications and Developments
L. Zhang (2008)
10.4238/2014.March.19.2
Inhibition effect of silver nanoparticles on herpes simplex virus 2.
R. Hu (2014)
10.1016/j.antiviral.2009.09.014
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
T. Cihlář (2010)
Pluronic ® block copolymers as novel polymer Therapeutic Advances in Infectious Disease
AV Kabanov (2002)
10.1039/c0cs00018c
Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies.
N. Khlebtsov (2011)
10.1016/j.vaccine.2012.09.036
A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles.
Dharmendra Raghuwanshi (2012)
10.1021/acs.molpharmaceut.5b00335
Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.
S. Adesina (2015)
10.2147/IJN.S7681
Progress in antiretroviral drug delivery using nanotechnology
R. Mallipeddi (2010)
10.1038/nm1268
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
T. Wakita (2005)
10.18433/J3RS3V
Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System.
M. Uddin (2015)
10.1371/journal.ppat.1004473
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
J. Elliott (2014)
10.1016/j.pep.2016.02.013
Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies.
Sibusiso B. Maseko (2016)
10.1038/mt.2008.127
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.
S. Muro (2008)
10.3762/bjnano.5.174
Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages
Dagmar A Kuhn (2014)
10.1111/cbdd.12690
Binding Free Energy Calculations of Nine FDA‐approved Protease Inhibitors Against HIV‐1 Subtype C I36T↑T Containing 100 Amino Acids Per Monomer
Husain A Lockhat (2016)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.3390/v4040488
Nanotechnology and the Treatment of HIV Infection
R. Parboosing (2012)
10.1002/hep.27847
Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication
K. Esser-Nobis (2015)
10.1006/VIRO.2002.1415
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
M. Skiadopoulos (2002)
10.1016/j.addr.2013.05.007
Targeting C-type lectin receptors with multivalent carbohydrate ligands.
B. Lepenies (2013)
10.1073/pnas.1207766109
Nanoparticle-based artificial RNA silencing machinery for antiviral therapy
Z. Wang (2012)
10.2174/1389203033487306
TAT peptide internalization: seeking the mechanism of entry.
E. Vivès (2003)
10.1164/rccm.201003-0422OC
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
M. Zamora (2011)
10.1126/scitranslmed.3003453
Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus
Laura M Ensign (2012)
10.1016/j.tibtech.2016.10.001
Electrochemical Biosensors for Early Stage Zika Diagnostics.
A. Kaushik (2017)
10.1021/nn2007496
Effect of gold nanoparticle aggregation on cell uptake and toxicity.
Alexandre Albanese (2011)
10.1007/s11095-016-1961-x
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?
Christian Lubich (2016)
10.2217/nnm.13.8
Therapeutic nanoparticles in clinics and under clinical evaluation.
Catherine A. Schütz (2013)
10.1080/10611860600965914
Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro
T. Dutta (2007)
10.1016/j.vaccine.2014.04.011
A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
V. Neuhaus (2014)
10.1371/journal.pbio.0020198
HIV Infection of Naturally Occurring and Genetically Reprogrammed Human Regulatory T-cells
K. Oswald-Richter (2004)
10.1186/1477-3155-9-30
Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds
H. H. Lara (2011)
10.2217/nnm.13.58
Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.
Wenqian Tao (2014)
10.1021/nl200636r
Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery.
Zhiyong Poon (2011)
10.1371/journal.pmed.1001997
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
J. Dunning (2016)
10.1016/j.jconrel.2016.01.008
Current applications of nanoparticles in infectious diseases.
H. Zazo (2016)
10.1128/JVI.78.15.8146-8158.2004
Role of Nucleolin in Human Parainfluenza Virus Type 3 Infection of Human Lung Epithelial Cells
S. Bose (2004)
10.1109/TNANO.2016.2516561
Nanoparticle-Mediated Nonviral DNA Delivery for Effective Inhibition of Influenza a Viruses in Cells
A. Levina (2016)
10.1002/CPLU.201100074
Synthesis and Stability of Highly Crystalline and Stable Iron/Iron Oxide Core/Shell Nanoparticles for Biomedical Applications
Soshan Cheong (2012)
10.1097/QAD.0b013e328011e691
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
R. Shafer (2007)
10.1007/s11095-006-0284-8
Nanotechnology: Intelligent Design to Treat Complex Disease
P. Couvreur (2006)
10.1039/C1PY00034A
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Steevens N S Alconcel (2011)
10.1021/ja710321g
Inhibition of HIV fusion with multivalent gold nanoparticles.
Mary-Catherine Bowman (2008)
10.1016/S0168-3659(00)00339-4
Biodegradable polymeric nanoparticles as drug delivery devices.
K. Soppimath (2001)
10.1038/srep24867
Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C
Liang Duan (2016)
10.1016/J.BIOPHA.2006.07.093
Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
N. Toub (2006)
10.2147/IJN.S25871
Anti-HIV-1 nanotherapeutics: promises and challenges for the future
S. Mahajan (2012)
10.1016/J.ELECTACTA.2005.04.071
THE STUDY OF ANTIMICROBIAL ACTIVITY AND PRESERVATIVE EFFECTS OF NANOSILVER INGREDIENT
K. H. Cho (2005)
10.4103/0250-474X.115457
Enhancement of Transdermal Penetration and Bioavailability of Poorly Soluble Acyclovir Using Solid Lipid Nanoparticles Incorporated in Gel Cream
P. Gide (2013)
10.3390/molecules200814051
Nanostructures for the Inhibition of Viral Infections
S. Szunerits (2015)
10.1016/j.ijpharm.2012.12.031
Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy.
D. Lembo (2013)
10.4314/TJPR.V8I3.44547
Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery
N. Ochekpe (2009)
10.1016/j.taap.2008.06.026
Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity.
Ronghui Lei (2008)
10.1002/0471743984.vse0549
[Antiviral drugs].
A. Denys (2011)
10.1007/s11095-007-9379-0
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
A. R. Jones (2007)
10.1021/AR9602664
Monolayer-protected cluster molecules.
A. C. Templeton (2000)
10.1016/B978-0-12-391858-1.00001-0
Enhanced antiviral activity of acyclovir loaded into nanoparticles.
R. Cavalli (2012)
10.1016/j.colsurfb.2010.05.016
Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles.
M. Moretton (2010)
10.1016/j.jid.2016.01.033
Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-Mediated Specific Immune Responses against HIV-1.
S. Caucheteux (2016)
10.1007/s11095-008-9626-z
Shape Induced Inhibition of Phagocytosis of Polymer Particles
J. Champion (2008)
10.1056/NEJMOA033364
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Y. Liaw (2004)
10.1016/S0264-410X(02)00512-1
Inflexal V a trivalent virosome subunit influenza vaccine: production.
R. Mischler (2002)
Liposomes encapsulating antiviral drugs, www.google
MG Bergeron (1998)
10.1038/nrd2591
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros (2010)
10.1007/s00018-008-7540-5
Integrase, LEDGF/p75 and HIV replication
E. Poeschla (2008)
10.1080/08982100600880432
The ‘Co-Delivery’ Approach to Liposomal Vaccines: Application to the Development of influenza-A and hepatitis-B Vaccine Candidates
P. Laing (2006)
10.1586/14760584.2016.1141054
Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination
J. J. Glass (2016)
10.1371/journal.pone.0018270
Activation of Latent HIV Using Drug-Loaded Nanoparticles
M. Kovochich (2011)
10.1371/journal.pone.0141050
Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles
Jessica Jenkins Broglie (2015)
10.1074/JBC.M410592200
Involvement of Toll-like Receptor 3 in the Immune Response of Lung Epithelial Cells to Double-stranded RNA and Influenza A Virus*
Loïc Guillot (2005)
10.1016/j.biotechadv.2008.09.002
Silver nanoparticles as a new generation of antimicrobials.
M. Rai (2009)
10.1007/s11095-005-7147-6
Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice
Manuela Pereira de Oliveira (2005)
Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products
Claudia Fruijtier-P (2005)
Handbook of nanostructured materials and nanotechnology
H. Nalwa (2000)
10.1371/journal.pone.0061416
Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis
T. Chaowanachan (2013)
10.1007/s11095-008-9697-x
Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?
P. Decuzzi (2008)
10.1371/journal.pone.0104113
Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes Simplex Virus Type 2 Infection
P. Orlowski (2014)
Doravirine is non-inferior to darunavir/r in phase 3 treatment-naive trial at week 48. In: Program and abstracts of the 2017 conference on retroviruses and opportunistic infections
J Molina (2017)
10.1016/j.vaccine.2016.02.033
Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
K. L. Bengtsson (2016)
10.1002/ANIE.200504599
Laser-induced release of encapsulated materials inside living cells.
A. Skirtach (2006)
10.1038/nature14442
Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates
E. Thi (2015)
10.1016/j.vetmic.2013.04.029
PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs
V. Dwivedi (2013)
10.1021/acs.molpharmaceut.5b00707
Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice.
F. Lebre (2016)
10.1073/pnas.0801763105
The effect of particle design on cellular internalization pathways
Stephanie E. A. Gratton (2008)
10.1016/J.JCONREL.2004.10.018
Cationic TAT peptide transduction domain enters cells by macropinocytosis.
I. Kaplan (2005)
Development and In Vitro-In Vivo Evaluation of Oral Drug Delivery System of Acyclovir Loaded PLGA nanoparticles.
U. V. Bhosale (2013)
10.1086/591851
Developing new antiviral agents for influenza treatment: what does the future hold?
F. Hayden (2009)
10.3109/21691401.2014.893522
Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells
A. Tahamtan (2015)
10.1016/j.biomaterials.2009.07.065
Antifungal activity of silver nanoparticles against Candida spp.
A. Panáček (2009)
10.1016/S0140-6736(10)60357-1
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
T. Geisbert (2010)
10.1016/S0001-706X(03)00120-7
Inactivation of Ebola virus with a surfactant nanoemulsion.
A. Chepurnov (2003)
10.22038/IJBMS.2014.3340
Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin
Maryam Mohajer (2014)
Silver nanoparticles inhibit replication of respiratory syncytial virus
L Sun (2008)
10.1016/j.ijpharm.2010.04.026
Potential neurotoxicity of nanoparticles.
Yu-Lan Hu (2010)
Advanced nanomaterials for biomedical applications
K. Medepalli (2008)
10.1038/mtm.2016.23
Production and clinical development of nanoparticles for gene delivery
J. Chen (2016)
10.1093/infdis/jiv406
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
G. Glenn (2016)
10.1038/nnano.2007.223
Immunological properties of engineered nanomaterials
M. Dobrovolskaia (2007)
10.1163/156856207779996931
Nanostructured materials for applications in drug delivery and tissue engineering
M. Goldberg (2007)
10.1021/AC00100A008
Preparation and Characterization of Au Colloid Monolayers
K. C. Grabar (1995)
10.2174/157341309787314566
Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins
D. Uskoković (2009)
10.1021/BM0501454
Polymersome encapsulated hemoglobin: a novel type of oxygen carrier.
D. R. Arifin (2005)
IN MICE
H. Goto (2009)
10.1007/s12272-013-0043-4
Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization
S. Dehghan (2013)
10.1016/S0168-3659(02)00009-3
Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery.
A. Kabanov (2002)
10.1016/j.biomaterials.2010.03.036
Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating.
H. Chen (2010)
10.1002/ddr.21010
Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management
N. Kuntworbe (2012)
10.4103/0974-777X.93764
Nanotechnology Applications to HIV Vaccines and Microbicides
S. Boyapalle (2012)
10.1097/01.COT.0000392690.64875.6C
Progress Being Made on Potential of Microbicides to Prevent Genital HPV Infection
P. Eastman (2010)
10.1074/jbc.M114.608315
Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation*
Arangassery Rosemary Bastian (2014)
10.1016/S0168-3659(03)00328-6
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles.
J. Panyam (2003)
10.1016/S0140-6736(00)04638-9
Herpes simplex virus infections
R. Whitley (2001)
10.3762/bjoc.10.136
Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs
F. Chiodo (2014)
10.1007/s11481-006-9032-4
Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
J. Kingsley (2006)
10.1002/jps.21392
Biowaiver monographs for immediate release solid oral dosage forms: aciclovir.
J. Arnal (2008)
10.1016/j.ijpharm.2009.10.018
Polymer-based nanocapsules for drug delivery.
C. E. Mora-Huertas (2010)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
Highly active antiretroviral therapy: current state of the art, new agents and Therapeutic Advances in Infectious Disease
G Barbaro (2005)
10.1021/nn501668a
Surface chemistry of gold nanoparticles mediates their exocytosis in macrophages.
N. Oh (2014)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
10.1038/nature12202
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
M. Kanekiyo (2013)
10.1016/j.nano.2012.11.001
Development of a nanoparticle-based influenza vaccine using the PRINT technology.
A. L. Galloway (2013)
10.1016/J.IJPHARM.2007.02.028
Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications.
J. L. Arias (2007)
10.1586/14760584.7.8.1141
Epaxal®: a virosomal vaccine to prevent hepatitis A infection
P. Bovier (2008)
10.1021/ACS.ANALCHEM.6B03109
Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals.
B. Chen (2016)
10.1002/JBM.A.10057
Room-temperature preparation and characterization of poly (ethylene glycol)-coated silica nanoparticles for biomedical applications.
Hao Xu (2003)
10.1111/2049-632X.12136
The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics
N. Shafagati (2014)
10.1016/j.vaccine.2013.11.069
Nanoparticle vaccines.
L. Zhao (2014)
10.1155/2015/601617
Core-shell nanocatalysts obtained in reverse micelles: structural and kinetic aspects
C. Tojo (2015)
10.1016/J.COPBIO.2007.11.008
Nanotoxicity: the growing need for in vivo study.
H. C. Fischer (2007)
10.1007/978-94-017-8739-0_5
Nanoparticles: cellular uptake and cytotoxicity.
Isaac M. Adjei (2014)
10.1039/c2cc33448h
Surface-modified protein nanospheres as potential antiviral agents.
Dana Baram-Pinto (2012)
10.1016/j.ijpharm.2010.08.026
Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment.
J. Wang (2010)
10.1002/SMLL.200400093
Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity.
E. E. Connor (2005)
10.2147/IJN.S109943
Advancements in nano-enabled therapeutics for neuroHIV management
A. Kaushik (2016)
10.1038/nbt1402
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
A. Akinc (2008)
10.3109/17435390.2010.536615
Stable nanoparticle aggregates/agglomerates of different sizes and the effect of their size on hemolytic cytotoxicity
J. Zook (2011)
10.1001/jama.2016.0904
The Emerging Zika Pandemic: Enhancing Preparedness.
Daniel Lucey (2016)
Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% SPL7013 gel L Singh, HG Kruger et al. journals.sagepub.com/home/tai 127 (VivaGel®) to assess expanded safety
A-B Moscicki (2012)
10.1042/BST0320021
Proteases of the complement system.
Robert B Sim (2004)
10.1128/JVI.78.8.4330-4341.2004
Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome
J. Towner (2004)
10.1016/j.cell.2008.05.009
Regulatory T Cells and Immune Tolerance
S. Sakaguchi (2008)
10.1056/NEJMp0900648
Global transmission of oseltamivir-resistant influenza.
A. Moscona (2009)
10.1016/j.colsurfb.2016.06.022
Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes.
D. Ramyadevi (2016)
10.4049/jimmunol.0802928
Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer1
S. Misumi (2009)
10.1166/JBN.2011.1332
AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration.
Pratikkumar A. Patel (2011)
10.1007/s11481-016-9692-7
Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection
Catherine Demarino (2016)
10.1088/0957-4484/21/28/285105
Non-specific cellular uptake of surface-functionalized quantum dots.
T. A. Kelf (2010)
10.2217/nnm.10.25
Conference scene: Nanoneuroprotection and nanoneurotoxicity: recent progress and future perspectives.
H. Sharma (2010)
10.1038/nmat2344
Physical approaches to biomaterial design.
S. Mitragotri (2009)
10.1097/QAD.0b013e328346bd3e
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)
I. McGowan (2011)
LEDGF / P 75 and HIV replication
C Demarino (2008)
10.2147/IJN.S114446
Potential inhibition of HIV-1 encapsidation by oligoribonucleotide–dendrimer nanoparticle complexes
R. Parboosing (2017)
10.1016/J.IJPHARM.2007.03.012
Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Y. Kuo (2007)
10.4049/jimmunol.168.11.5786
C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase1
J. Andersson (2002)
10.1016/j.addr.2009.03.009
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.
P. Aggarwal (2009)
10.1002/biot.201100054
Current progress of siRNA/shRNA therapeutics in clinical trials
J. Burnett (2011)
Treatment of herpes simplex virus infections
R. Snoeck (1999)
10.1002/etc.2470
Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type.
Katja Kettler (2014)
10.1021/mp800051m
Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
F. Alexis (2008)
10.3109/21691401.2014.883400
Nanotechnology: A magic bullet for HIV AIDS treatment
L. Kumar (2015)
10.1021/BC049951I
Toxicity of gold nanoparticles functionalized with cationic and anionic side chains.
Catherine M Goodman (2004)
10.1016/j.cis.2013.12.008
Core/shell nanoparticles in biomedical applications.
Krishnendu Chatterjee (2014)
10.1056/NEJM199804303381808
HIV-protease inhibitors.
C. Flexner (1998)
10.1186/1477-3155-8-1
Mode of antiviral action of silver nanoparticles against HIV-1
H. H. Lara (2010)
10.1111/j.1365-2605.2007.00865.x
Effect of nanoparticles on the male reproductive system of mice.
S. Yoshida (2009)
10.1111/j.1747-0285.2006.00454.x
Influence of Generation 2–5 of PAMAM Dendrimer on the Inhibition of Tat Peptide/ TAR RNA Binding in HIV‐1 Transcription
W. Wang (2006)
10.1016/S1359-6446(03)02903-9
Nanotech approaches to drug delivery and imaging.
S. Sahoo (2003)
10.1136/bmj.i657
Zika virus is a global public health emergency, declares WHO
A. Gulland (2016)
10.1016/j.nano.2016.08.016
Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.
Tejabhiram Yadavalli (2017)
10.1002/3527602453
Nanobiotechnology :concepts, applications and perspectives
C. Niemeyer (2005)
10.1016/j.tibtech.2008.04.005
Multifunctional nanoparticles--properties and prospects for their use in human medicine.
Nuria Sanvicens (2008)
10.1016/J.JCONREL.2006.04.012
Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
Y. Sudhakar (2006)
10.1038/cr.2009.139
Complement and its role in innate and adaptive immune responses
Jason R Dunkelberger (2010)
10.1002/RMV.352
Functional balance between haemagglutinin and neuraminidase in influenza virus infections
R. Wagner (2002)
10.1088/0957-4484/18/28/285604
Preparation and antibacterial activity of Fe3O4@Ag nanoparticles
P. Gong (2007)
10.1016/j.nano.2011.01.017
Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles.
D. Chiappetta (2011)
10.1007/s13346-011-0036-0
Enhanced dermal delivery of acyclovir using solid lipid nanoparticles
S. Jain (2011)
10.1021/acsami.6b06613
Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways.
Y. Li (2016)
10.1371/journal.pone.0145760
Nanotechnology as a New Therapeutic Approach to Prevent the HIV-Infection of Treg Cells
Didiana Jaramillo-Ruiz (2016)
10.2174/138161209787846793
Clinical experience with therapeutic vaccines designed for patients with hepatitis.
Dendev Batdelger (2009)
10.1179/000349803235001840
Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis
E. Cauchetier (2003)
10.1016/j.cell.2007.02.042
Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide
J. Münch (2007)
10.1002/cld.577
New pharmacological approaches to a functional cure of hepatitis B
W. Seto (2016)
10.1016/j.bios.2015.01.035
An amplified electrochemical immunosensor based on in situ-produced 1-naphthol as electroactive substance and graphene oxide and Pt nanoparticles functionalized CeO2 nanocomposites as signal enhancer.
Zhe-han Yang (2015)
10.1016/j.antiviral.2009.10.007
Current status and challenges of antiretroviral research and therapy.
J. Esté (2010)
International Approvals: Avalox IV, Pegasys
Y. Waknine (2005)
10.1111/j.1440-1711.2005.01315.x
Lipid based particulate formulations for the delivery of antigen
M. J. Copland (2005)
10.1002/CHIN.201402252
Dendrimers as Macromolecular Tools to Tackle from Colon to Brain Tumor Types: A Concise Overview
S. Mignani (2014)
10.1146/annurev-bioeng-071910-124709
In vivo delivery of RNAi with lipid-based nanoparticles.
L. Huang (2011)
10.2147/IJN.S28531
Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages
Shann S. Yu (2012)
10.1097/QAI.0000000000000092
HIV Infection Deregulates the Balance Between Regulatory T Cells and IL-2–Producing CD4 T Cells by Decreasing the Expression of the IL-2 Receptor in Treg
G. Méndez-Lagares (2014)
10.1042/CS20050369
Molecular biology of human papillomavirus infection and cervical cancer.
J. Doorbar (2006)
10.1016/j.addr.2009.11.024
Nanotechnology applied to the treatment of malaria.
N. S. Santos-Magalhães (2010)
10.1166/JBN.2014.1813
Pegylation increases platelet biocompatibility of gold nanoparticles.
M. Santos-Martinez (2014)
10.3748/wjg.v21.i44.12558
Hepatitis B virus therapy: What's the future holding for us?
S. Manzoor (2015)
10.2147/IJN.S50070
Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3
S. Gaikwad (2013)
10.1016/j.biomaterials.2011.11.057
The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli.
Yan Cui (2012)
10.1038/nri2868
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
M. Bachmann (2010)
10.1074/jbc.M112.437202
Sialylneolacto-N-tetraose c (LSTc)-bearing Liposomal Decoys Capture Influenza A Virus*
G. Hendricks (2013)
10.1515/EJNM.2010.3.1.34
Nanopharmaceuticals: Nanopharmaceuticals
Raj Bawa (2010)
10.1007/BFB0118109
Large clusters and colloids. Metals in the embryonic state
G. Schmid (1992)
10.1016/j.antiviral.2012.09.020
Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection.
Thessicar E Antoine (2012)
10.1371/journal.pone.0069773
Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
O. Abián (2013)
10.1039/c3an01406a
Measuring and modelling cell-to-cell variation in uptake of gold nanoparticles.
J. C. Jeynes (2013)
10.1021/acs.molpharmaceut.5b00544
Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Y. Jiang (2015)
10.1016/j.pharmthera.2013.06.008
New perspectives in nanomedicine.
A. Thorley (2013)
10.2147/IJN.S56127
Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs
B. Binjawadagi (2014)
10.2147/NSA.S35506
Potential of magnetic nanoparticles for targeted drug delivery.
Hung-Wei Yang (2012)
10.1016/j.jconrel.2011.09.098
The journey of a drug-carrier in the body: an anatomo-physiological perspective.
N. Bertrand (2012)
10.1166/JNN.2014.9578
Nanotechnology for diagnosis and treatment of infectious diseases.
M. Qasim (2014)
10.2174/1381612820666141014125213
A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma.
Wen Li (2015)
10.1016/S0169-409X(01)00227-7
Targeted drug conjugates: principles and progress.
M. Garnett (2001)
10.1615/CRITREVTHERDRUGCARRIERSYST.2013005469
Nanomedicines for treatment of viral diseases.
Rujuta Mehendale (2013)
Trivalent inactivated subunit influenza
K Giezeman
10.1073/pnas.0912186107
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
J. Devincenzo (2010)
10.1016/j.bmcl.2010.03.070
Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues.
Joachim Caron (2010)
10.1208/s12249-013-0058-7
Chitosan Nanoparticle Encapsulated Hemagglutinin-Split Influenza Virus Mucosal Vaccine
Chompoonuch Sawaengsak (2013)
10.4155/tde-2017-0013
Biomimetic and bioinspired nanoparticles for targeted drug delivery.
M. Gagliardi (2017)
10.1128/JVI.02005-07
The Influenza Virus Resource at the National Center for Biotechnology Information
Y. Bào (2007)
10.1016/j.jconrel.2012.06.008
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.
Jill M. Steinbach (2012)
10.1039/B510984A
Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells.
R. W. Sun (2005)
10.1007/s11095-007-9284-6
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
L. E. V. Vlerken (2007)
10.1039/c4lc01033g
Integration of reverse transcriptase loop-mediated isothermal amplification with an immunochromatographic strip on a centrifugal microdevice for influenza A virus identification.
J. H. Jung (2015)
10.1080/MMY.38.S1.335.347
New targets and delivery systems for antifungal therapy.
T. Walsh (2000)
10.1016/j.nano.2009.07.002
Biological synthesis of metallic nanoparticles.
Kaushik N. Thakkar (2010)
10.1038/nm1319
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G. Faetkenheuer (2005)
10.2147/IJN.S45886
Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system
M. J. Gomes (2014)
VivaGel™ (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection
R. Rupp (2007)
10.2147/IJN.S596
Drug delivery and nanoparticles: Applications and hazards
W. D. de Jong (2008)
10.1002/CHIN.201032264
Gold Nanoparticles for Biology and Medicine
D. Giljohann (2010)
10.1016/j.jconrel.2011.07.002
"Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era.
Ae Jung Huh (2011)
10.3389/fcimb.2013.00013
Vaccine delivery using nanoparticles
A. Gregory (2013)
10.1111/j.1651-2227.2004.tb02971.x
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile
S. Riedemann (2004)
10.1016/j.ijpharm.2008.04.036
Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Y. Perrie (2008)
10.1097/QAI.0b013e31823f2aeb
Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded Safety
Anna-Barbara Moscicki (2012)
10.1002/mabi.201500094
Shell Cross-Linked Polymeric Micelles as Camptothecin Nanocarriers for Anti-HCV Therapy.
I. Jiménez-Pardo (2015)
10.1038/srep25309
Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers
Ajeet Kaushik (2016)
10.1517/17425247.2012.720969
Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents
R. Garay (2012)
10.1186/1741-7015-10-104
New treatments for influenza
S. Barik (2012)
10.1097/00019048-200205000-00048
ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV
J. Church (2003)
10.1016/J.ANTIVIRAL.2009.09.008
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)
M. Béthune (2010)
10.1016/j.colsurfb.2015.10.045
Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir.
Bandar E Aldhubiab (2015)
10.1016/J.MOLIMM.2005.02.006
Complement activation and protein adsorption by carbon nanotubes.
Carolina Salvador-Morales (2006)
10.1021/mp300559v
Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration.
Abdul Khader Mohammad (2013)
10.1038/nature08157
Emergence and pandemic potential of swine-origin H1N1 influenza virus
G. Neumann (2009)
10.1016/j.vaccine.2009.02.008
Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity.
K. Giezeman (2009)
Herpes simplex virus.
J. W. Duggan (1961)
10.1136/adc.2005.072918
Is polyethylene glycol safe and effective for chronic constipation in children?
R. Arora (2005)
10.1016/j.addr.2008.03.016
Gold nanoparticles in delivery applications.
P. Ghosh (2008)
10.1016/j.addr.2009.11.018
Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting.
U. Gupta (2010)
10.1146/annurev-food-030713-092354
Nanodelivery of bioactive components for food applications: types of delivery systems, properties, and their effect on ADME profiles and toxicity of nanoparticles.
T. Borel (2014)
10.1007/978-1-60327-198-1_1
Unique benefits of nanotechnology to drug delivery and diagnostics.
S. Mcneil (2011)
10.1016/j.jconrel.2014.05.034
Biodegradable nanoparticles for intracellular delivery of antimicrobial agents.
Shuyu Xie (2014)
10.1016/j.biomaterials.2011.10.058
Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment.
A. Kumar (2012)
10.1524/teme.1995.62.jg.213
Biosensoren: Grundlagen und Anwendungen
F. Scheller (1995)
10.2165/00003088-198308030-00001
Clinical Pharmacokinetics of Acyclovir
O. Laskin (1983)
10.1109/TMAG.2008.2002250
Iron Oxide Versus Fe $_{55}$ Pt $_{45}$ /Fe $_{3}$ O $_{4}$ : Improved Magnetic Properties of Core/Shell Nanoparticles for Biomedical Applications
L. C. Varanda (2008)
10.1088/2043-6262/7/4/045013
Intracellular localization of gold nanoparticles with targeted delivery in MT-4 lymphocytes
Lavanya Singh (2016)
10.1016/j.ijpharm.2011.05.053
Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
P. Zeng (2011)
Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity.
Héctor Chapoy-Villanueva (2015)
10.1186/s12951-015-0156-7
Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles
Einar Sulheim (2016)
10.1159/000233512
Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors.
A. W. Richter (1984)
10.1086/499406
The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs.
S. Cosgrove (2006)
10.1016/j.nano.2016.02.015
Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2.
Jae-Su Moon (2016)
10.2217/nnm.12.62
Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.
M. Tan (2012)
10.1038/PHYSCI241020A0
Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions
G. Frens (1973)
10.1016/j.addr.2016.02.010
Role of nanotechnology in HIV/AIDS vaccine development.
Y. Liu (2016)
10.1016/S2055-6640(20)30489-1
CNS reservoirs for HIV: implications for eradication
J. Hellmuth (2015)
10.1016/J.AMJMED.2005.07.012
Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination.
M. Sjogren (2005)
10.1021/cr100449n
Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications.
Rajib Ghosh Chaudhuri (2012)
10.1371/journal.pone.0016258
A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days
C. Cohen (2011)
10.1128/JVI.01352-09
Human Regulatory T Cells Are Targets for Human Immunodeficiency Virus (HIV) Infection, and Their Susceptibility Differs Depending on the HIV Type 1 Strain
Maria E. Moreno-Fernandez (2009)
10.1016/j.vaccine.2015.05.015
MPG-based nanoparticle: An efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7.
Tayebeh Saleh (2015)
10.1016/j.yexmp.2008.12.004
Nanoparticle-based targeted drug delivery.
R. Singh (2009)
10.1021/nn302538y
Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection.
M. Lee (2012)
10.1016/j.addr.2016.02.008
Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.
M. Nair (2016)
10.1039/DF9511100055
A study of the nucleation and growth processes in the synthesis of colloidal gold
J. Turkevich (1951)
10.1039/C39940000801
Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system
M. Brust (1994)
10.1021/ES801251C
Aggregation kinetics of multiwalled carbon nanotubes in aquatic systems: measurements and environmental implications.
Navid B Saleh (2008)
10.3797/scipharm.1502-01
Activation of HIV-1 with Nanoparticle-Packaged Small-Molecule Protein Phosphatase-1-Targeting Compound
Kahli A. Smith (2015)
10.2217/nnm.10.1
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.
T. Mamo (2010)
10.1039/C6BM00276E
Recent trends on hydrogel based drug delivery systems for infectious diseases.
A. Vashist (2016)



This paper is referenced by
10.30574/gscbps.2020.10.2.0018
The importance of nanotechnology and drug carrier systems in pharmacology
Yerebasan Ulku (2020)
10.2147/IJN.S221433
Breakthroughs in medicine and bioimaging with up-conversion nanoparticles
Iman Rostami (2019)
10.1080/00016357.2020.1810769
The effectiveness and efficacy of respiratory protective equipment (RPE) in dentistry and other health care settings: a systematic review
L. Samaranayake (2020)
10.3390/nano10020183
Multifunctional Nanocarriers for Lung Drug Delivery
J. R. Pontes (2020)
10.3390/challe11020015
Nanotechnology as an Alternative to Reduce the Spread of COVID-19
Roberto Vazquez-Munoz (2020)
10.3390/pharmaceutics12020171
Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers
Florina-Daniela Cojocaru (2020)
10.2147/ITT.S241064
Immunoinformatics and Vaccine Development: An Overview
A. Oli (2020)
Nanotechnology: A promising approach of antiviral treatments against chikungunya virus (CHIKV)
R. Kumar (2019)
10.4155/fmc-2018-0452
Advances in drug delivery, gene delivery and therapeutic agents based on dendritic materials.
M. Contin (2019)
10.1016/j.nano.2019.03.004
Nano-based approach to combat emerging viral (NIPAH virus) infection
Rout George Kerry (2019)
10.1007/s12272-018-1008-4
Recent progress in dendrimer-based nanomedicine development
Yejin Kim (2018)
10.3390/nano10061072
Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses
M. Nasrollahzadeh (2020)
10.1016/j.biomaterials.2019.119441
Synthesis of a long acting nanoformulated emtricitabine ProTide.
Dhruvkumar Soni (2019)
10.1002/mabi.202000196
Antiviral Activity of Nanomaterials against Coronaviruses.
Wali Muhammad (2020)
10.3389/fmicb.2020.00431
Grand Challenge in Human/Animal Virology: Unseen, Smallest Replicative Entities Shape the Whole Globe
A. Adachi (2020)
10.3390/nano10091645
Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?
S. Gurunathan (2020)
10.1007/s10876-019-01533-8
Engineered Nanomaterials as Potential Candidates for HIV Treatment: Between Opportunities and Challenges
M. Abd Elkodous (2019)
10.3389/fchem.2018.00237
Application of Light Scattering Techniques to Nanoparticle Characterization and Development
P. Carvalho (2018)
10.1007/978-981-32-9898-9_1
Current Advances in Nanotechnology and Medicine
S. Saxena (2020)
10.3390/pathogens9050350
Silver Nanoparticles as a Novel Potential Preventive Agent against Acanthamoeba Keratitis
Edyta B Hendiger (2020)
10.3390/antibiotics9080461
Bismuth Nanoantibiotics Display Anticandidal Activity and Disrupt the Biofilm and Cell Morphology of the Emergent Pathogenic Yeast Candida auris
Roberto Vazquez-Munoz (2020)
10.3389/fphar.2019.00751
Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases
G. Yang (2019)
10.1038/s41467-018-07755-0
Monitoring drug nanocarriers in human blood by near-infrared fluorescence correlation spectroscopy
Inka Negwer (2018)
10.1371/journal.pone.0227231
An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect
M. Hamdi (2020)
10.3390/biomimetics5020027
Metal Oxide Nanoparticles as Biomedical Materials
Maria P Nikolova (2020)
10.3390/AGRICULTURE10100444
Nanoparticles as Potential Antivirals in Agriculture
M. Vargas-Hernandez (2020)
10.1007/978-3-030-43855-5
Preclinical Evaluation of Antimicrobial Nanodrugs
J. Bueno (2020)
10.1016/j.nantod.2020.100962
Multivalent nanomedicines to treat COVID-19: A slow train coming
Tanveer A. Tabish (2020)
10.1111/cmi.12944
Masters of manipulation: Viral modulation of the immunological synapse
Rebecca J Bayliss (2018)
10.4155/tde-2020-0069
The potential role of nanomedicine on COVID-19 therapeutics
R. Mainardes (2020)
10.1007/s12195-020-00630-3
The Impact of COVID-19 on Cancer Risk and Treatment
Nidhi Jyotsana (2020)
10.1016/j.ejps.2018.10.017
Combination drug therapy via nanocarriers against infectious diseases.
Pavan Walvekar (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar